[go: up one dir, main page]

MX2009005551A - Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda. - Google Patents

Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.

Info

Publication number
MX2009005551A
MX2009005551A MX2009005551A MX2009005551A MX2009005551A MX 2009005551 A MX2009005551 A MX 2009005551A MX 2009005551 A MX2009005551 A MX 2009005551A MX 2009005551 A MX2009005551 A MX 2009005551A MX 2009005551 A MX2009005551 A MX 2009005551A
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
acute myeloid
treatment
iap inhibitors
iap
Prior art date
Application number
MX2009005551A
Other languages
English (en)
Inventor
Leigh Zawel
Yao Yao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009005551A publication Critical patent/MX2009005551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a método para el tratamiento de malignidades hematológicas, incluyendo leucemia mieloide aguda (AML), los cuales comprenden el uso de compuestos que inhiben el enlace de la proteína Smac a las IAPs ("inhibidor de IAP"). La presente invención también se refiere al uso de inhibidores de IAP para la preparación de un medicamento para el tratamiento de malignidades hematológicas, incluyendo leucemia mieloide aguda.
MX2009005551A 2006-11-28 2007-11-26 Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda. MX2009005551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86745006P 2006-11-28 2006-11-28
PCT/US2007/085486 WO2008085610A1 (en) 2006-11-28 2007-11-26 Use of iap inhibitors for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
MX2009005551A true MX2009005551A (es) 2009-06-08

Family

ID=39342685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005551A MX2009005551A (es) 2006-11-28 2007-11-26 Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.

Country Status (11)

Country Link
US (1) US20100076013A1 (es)
EP (1) EP2089027A1 (es)
JP (1) JP2010511057A (es)
KR (1) KR20090083412A (es)
CN (1) CN101541325A (es)
AU (1) AU2007342225A1 (es)
BR (1) BRPI0719559A2 (es)
CA (1) CA2670270A1 (es)
EA (1) EA200900691A1 (es)
MX (1) MX2009005551A (es)
WO (1) WO2008085610A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0617751A2 (pt) 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc BINDING COMPOUNDS TO THE IAP BIR DOMAIN
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
EP2478358A1 (en) * 2009-09-18 2012-07-25 Novartis AG Biomarkers for iap inhibitor compounds
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238650A1 (en) * 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
SG152225A1 (en) * 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
RU2008129630A (ru) * 2005-12-20 2010-01-27 Новартис АГ (CH) Комбинация органических соединений
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
EP2089027A1 (en) 2009-08-19
US20100076013A1 (en) 2010-03-25
CN101541325A (zh) 2009-09-23
EA200900691A1 (ru) 2009-12-30
WO2008085610A1 (en) 2008-07-17
KR20090083412A (ko) 2009-08-03
CA2670270A1 (en) 2008-07-17
AU2007342225A1 (en) 2008-07-17
JP2010511057A (ja) 2010-04-08
BRPI0719559A2 (pt) 2014-01-21

Similar Documents

Publication Publication Date Title
MX2009005551A (es) Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.
IL198551A0 (en) Combination of iap inhibitors and flt3 inhibitors
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
TN2009000224A1 (en) Inhibitors of akt activity
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2006091395A3 (en) Inhibitors of akt activity
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
TW200738234A (en) Triazole compounds that modulate HSP90 activity
WO2007139960A3 (en) Compounds that modulate hsp90 activity and methods for identifying same
WO2008091620A3 (en) Combination therapy comprising romidepsin and i.a. bortezomib
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2010021934A3 (en) Azaindole inhibitors of iap
WO2007131736A3 (en) Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
WO2006110638A3 (en) Inhibitors of akt activity
ZA200901921B (en) Pyrazolopyrimidine derivative
WO2006091542A3 (en) Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
WO2008072952A3 (en) Anti-inflammatory compounds containing compositions for treatment of cancer
WO2006068796A3 (en) Inhibitors of akt activity
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
GB2420498B (en) Compounds inhibiting the binding of sap for treating osteoarthritis
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких

Legal Events

Date Code Title Description
FA Abandonment or withdrawal